Drug Does Not Stall Memory Loss during Early Onset of Alzheimer’s

Mematime is an approved drug for Alzheimer’s patients

According to a new study, Mematime will not assist patients to reduce the loss of memory and other cognitive functions during the early onset of Alzheimer’s disease. The drug has been approved by the United States Food and Drug Administration authorities for using in patients who are suffering from advanced stages of this illness.

Drug not effective to stop dementia

The drug Mematime is prescribed to one among five patients of Alzheimer’s disease in patients whose loss in memory is considered as mild. However, the progress of the memory loss known as dementia is not curtailed by the use of this medication. Moreover, the progress of the memory loss and loss of other cognitive functionalists continues at the same rate as those patients who do not take any medications for their condition. The study included numerous clinical trials findings to derive at the effectiveness of Mematime for mild cognitive impairment.

Off label prescription is common

The drug is manufactured by Forest Labs Inc. in the United States of America. Although, the FDA denied approving this drug as a treatment for moderate Alzheimer’s patients in 2005, the off label prescription of this drug continues to be widespread and legal. Also known as Nemenda, the makers of this drug, sponsored a clinical research to prove the benefits of this drug for patients suffering from mild to severe Alzheimer’s disease.

New study contradicts the results

However, the new study that included results from seven different studies has proven the contrary. These clinical trials studied the effectiveness of the drug’s administration on patients suffering from mild to moderate Alzheimer’s or mild cognitive impairment, which is a condition that often precedes the onset of Alzheimer’s dementia. None of the results from the seven clinical trials proved that patients using this drug were benefited by curtailing the spread of the disease to its complete severity.

Manufacturer’s trials erroneous

The authors of this new study have hinted that the research undertaken by the drug manufacturer may have been incorrect. The results have not been warranted by the number of patients suffering from mild Alzheimer’s and were participants of the study. Moreover, the authors suggested that the researchers and the clinicians involved in Forest Labs Inc’s sponsored study aggressively prescribed the drugs without turning the results of this study for a stronger evidence of the drug’s effectiveness to curtail loss of memory.